Publications by authors named "R de Jongh"

Introduction: Upon infection, T cell-driven B cell responses in GC reactions induce memory B cells and antibody-secreting cells that secrete protective antibodies. How formation of specifically long-lived plasma cells is regulated via the interplay between specific B and CD4+ T cells is not well understood. Generally, antibody levels decline over time after clearance of the primary infection.

View Article and Find Full Text PDF
Article Synopsis
  • Methotrexate (MTX) is a common medicine for rheumatoid arthritis, but it may affect how well people’s immune systems respond to vaccines and infections.
  • In a study, researchers looked at how MTX treatment affected immune responses in patients who received a COVID-19 vaccine compared to healthy people and others not on MTX.
  • They found that while many immune cells were similar between patients and controls, those on MTX had fewer activated CD4 T cells, leading to slower antibody responses after vaccination.
View Article and Find Full Text PDF

Background: COPD is a common, preventable and treatable airway disease, and is currently the third leading cause of death worldwide. About one billion people worldwide are estimated to have vitamin D deficiency or insufficiency. Vitamin D deficiency is common among people with COPD, and has been reported to be associated with reduced lung function and increased risk of acute exacerbations of COPD.

View Article and Find Full Text PDF
Article Synopsis
  • * The European Renal Osteodystrophy (EUROD) initiative emphasizes the importance of a multidisciplinary team (MDT) approach, bringing together specialists to tackle complex cases of CKD-associated osteoporosis.
  • * The establishment of kidney-bone MDTs is recommended to enhance diagnostics and personalized treatment plans for improve patient management in CKD-MBD across different levels of healthcare.
View Article and Find Full Text PDF

Intermediate-length repeat expansions in ATAXIN-2 (ATXN2) are the strongest genetic risk factor for amyotrophic lateral sclerosis (ALS). At the molecular level, ATXN2 intermediate expansions enhance TDP-43 toxicity and pathology. However, whether this triggers ALS pathogenesis at the cellular and functional level remains unknown.

View Article and Find Full Text PDF